<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04618393</url>
  </required_header>
  <id_info>
    <org_study_id>EMB02X101</org_study_id>
    <nct_id>NCT04618393</nct_id>
  </id_info>
  <brief_title>A Study of EMB-02 in Participants With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I/II Trial of EMB-02, a Bi-specific Antibody Against PD-1 and LAG-3, in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai EpimAb Biotherapeutics Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai EpimAb Biotherapeutics Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and&#xD;
      schedule assessed to be safe for EMB-02 and to characterize the safety and tolerability of&#xD;
      EMB-02 at the RP2Ds. Pharmacokinetics (PK), immunogenicity, and the anti-tumor activity of&#xD;
      EMB-02 will also be assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I/II, multi-center, open label, multiple-dose, first in human study, designed&#xD;
      to assess safety and tolerability, and to identify the maximum tolerated dose (MTD) and/or&#xD;
      recommended Phase 2 dose (RP2D) for EMB-02 in patients with advanced solid tumors.&#xD;
      Pharmacokinetics, pharmacodynamics, immunogenicity, and response will also be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Dose escalation followed by Cohort Expansion Phase at the RP2D.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events as assessed by CTCAE V5.0</measure>
    <time_frame>Screening up to follow-up (30 days after the last dose)</time_frame>
    <description>Incidence and severity of AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of serious adverse events (SAE)</measure>
    <time_frame>Screening up to follow-up (30 days after the last dose)</time_frame>
    <description>Incidence of SAE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose interruptions</measure>
    <time_frame>Screening up to follow-up (30 days after the last dose)</time_frame>
    <description>Incidence of dose interruptions of EMB-02 during treatment as a measure of tolerability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose intensity</measure>
    <time_frame>Screening up to follow-up (30 days after the last dose)</time_frame>
    <description>Actual amount of drug taken by patients divided by the planned amount.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of DLTs during the first cycle of treatment.</measure>
    <time_frame>First infusion to the end of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>The Dose Limiting Toxicities (DLTs) are based on drug related adverse events and are specifically defined in study protocol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>From the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, expected average 6 months</time_frame>
    <description>Measured by RECIST 1.1, only applicable in Phase II part</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve (AUC) of EMB-02</measure>
    <time_frame>Through treatment until EOT visit, expected average 6 months</time_frame>
    <description>Blood samples for serum PK analysis will be obtained (AUC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentration (Cmax) of EMB-02</measure>
    <time_frame>Through treatment until EOT visit, expected average 6 months</time_frame>
    <description>Blood samples for serum PK analysis will be obtained (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentration (Ctrough) of EMB-02</measure>
    <time_frame>Through treatment until EOT visit, expected average 6 months</time_frame>
    <description>Blood samples for serum PK analysis will be obtained (Ctrough)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average concentration over a dosing interval (Css, avg)of EMB-02.</measure>
    <time_frame>Through treatment until EOT visit, expected average 6 months</time_frame>
    <description>Blood samples for serum PK analysis will be obtained (Css, avg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (T1/2) of EMB-02</measure>
    <time_frame>Through treatment until EOT visit, expected average 6 months.</time_frame>
    <description>Blood samples for serum PK analysis will be obtained (T1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic clearance (CL) of EMB-02</measure>
    <time_frame>Through treatment until EOT visit, expected average 6 months</time_frame>
    <description>Blood samples for serum PK analysis will be obtained (CL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady state volume of distribution (Vss) of EMB-02</measure>
    <time_frame>Through treatment until EOT visit, expected average 6 months</time_frame>
    <description>Blood samples for serum PK analysis will be obtained (Vss).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) of EMB-02 as assessed by RECIST 1.1</measure>
    <time_frame>From the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, expected average 6 months</time_frame>
    <description>Preliminary anti-tumor activity of EMB-02 will be obtained (PFS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response of EMB-02 as assessed by RECIST 1.1</measure>
    <time_frame>From the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, expected average 6 months</time_frame>
    <description>Preliminary anti-tumor activity of EMB-02 will be obtained (DOR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and titer of anti-drug antibodies stimulated by EMB-02</measure>
    <time_frame>Up to End of Treatment Follow Up Period (30 days after the last dose)</time_frame>
    <description>Antibodies to EMB-02 will be assessed to evaluate potential immunogenicity.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>EMB-02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Phase I part: participants enrolled in the different time will receive EMB-02 once weekly (IV) at different ascending dose levels.&#xD;
In Phase II part: participants will receive EMB-02 once weekly (IV) at previously defined RP2D.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EMB-02</intervention_name>
    <description>EMB-02 is a FIT-Ig® bispecific antibody against PD-1 and LAG-3.</description>
    <arm_group_label>EMB-02</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide written informed consent.&#xD;
&#xD;
          -  Phase I: Patients with histologically or cytologically confirmed locally&#xD;
             advanced/metastatic solid tumors and have failed (progressed on, or are intolerant of)&#xD;
             standard therapies. Moreover, the disease should be measurable or evaluable per RECIST&#xD;
             v1.1&#xD;
&#xD;
          -  Phase II Cohort A: Patients with histologically or cytologically confirmed locally&#xD;
             advanced/metastatic melanoma, excluding uveal melanoma. &gt; 1 prior therapy, including&#xD;
             prior treatment with PD-1/L1(mandatory) and/or CTLA-4 inhibitors(optional). And the&#xD;
             disease is measurable or evaluable per RECIST v1.1&#xD;
&#xD;
          -  Archival tumor samples available for retrospective analysis or biopsy will be taken.&#xD;
&#xD;
          -  ECOG performance status 0 or 1 for phase I, and ≤2 for phase II; life expectancy &gt; 3&#xD;
             Months&#xD;
&#xD;
          -  Adequate organ function to participate in the trial.&#xD;
&#xD;
          -  Recovery from adverse events (AEs) related to prior anticancer therapy.&#xD;
&#xD;
          -  Highly effective contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have active autoimmune disease or history of autoimmune disease&#xD;
&#xD;
          -  History of severe irAE.&#xD;
&#xD;
          -  History of severe allergic reactions&#xD;
&#xD;
          -  Use of systemic corticosteroids.&#xD;
&#xD;
          -  Symptomatic central nervous system metastases.&#xD;
&#xD;
          -  Patients with cardiac dysfunction&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus with hemoglobin A1c &gt; 8% (via medical history)&#xD;
&#xD;
          -  Prior treatment with a LAG-3 inhibitor&#xD;
&#xD;
          -  Anticancer therapy or radiation &lt; 5 half-lives or 4 weeks (whichever is shorter) prior&#xD;
             to study treatment;&#xD;
&#xD;
          -  Prior organ or stem cell/bone marrow transplant.&#xD;
&#xD;
          -  Concurrent malignancy &lt; 5 years prior to entry.&#xD;
&#xD;
          -  Patients with active infections.&#xD;
&#xD;
          -  Major surgery &lt; 4 weeks or minor surgery &lt; 2 weeks prior to study treatment&#xD;
&#xD;
          -  Live virus vaccines &lt; 30 days prior to screening&#xD;
&#xD;
          -  Pregnant or breast-feeding females&#xD;
&#xD;
          -  Any investigational agents or study drugs from a previous clinical study within 30&#xD;
             days of the first dose of study treatment&#xD;
&#xD;
          -  Any other serious underlying medical conditions&#xD;
&#xD;
          -  Abuse on alcohol, cannabis- derived products or other drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shuqi Zeng</last_name>
    <phone>+8618621781427</phone>
    <email>shqzeng@epimab.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhongqi Wu</last_name>
    <phone>+8613501633946</phone>
    <phone_ext>+8613501633946</phone_ext>
    <email>zqwu@epimab.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado Health Medical Group</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia &quot;Lisa&quot; Deschaine, BS, CCRC, RMA</last_name>
      <phone>719-365-6855</phone>
      <email>Alicia.Deschaine@uchealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Graf, MS CCRP</last_name>
      <phone>719-365-6173</phone>
      <email>Elizabeth.Graf@uchealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Hoyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prisma Health-Upstate</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona Davidson, BSN, RN, CTR</last_name>
      <phone>864-455-3737</phone>
      <email>Fiona.Davidson@prismahealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Jill Roemmich, RN</last_name>
      <phone>864-455-6962</phone>
      <email>Jill.Roemmich@prismahealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ki Y Chung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>W. Jeff Edenfield, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peninsula &amp; South Eastern Haematology &amp; Oncology Group (PASO)</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert, Goikhman, RN, CNC</last_name>
      <phone>+613 91131307</phone>
      <email>ag@paso.com.au</email>
    </contact>
    <contact_backup>
      <last_name>Anne Marie Lobo-Davis, BSN</last_name>
      <phone>+613 91131310</phone>
      <email>al@paso.com.au</email>
    </contact_backup>
    <investigator>
      <last_name>Vinod Ganju, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 18, 2020</study_first_submitted>
  <study_first_submitted_qc>November 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I/II</keyword>
  <keyword>Bispecific antibody</keyword>
  <keyword>PD-1</keyword>
  <keyword>LAG-3</keyword>
  <keyword>EMB-02</keyword>
  <keyword>Immuno-oncology</keyword>
  <keyword>dose escalation</keyword>
  <keyword>cohort expansion</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Neoplasm Metastasis</keyword>
  <keyword>advanced solid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

